Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Cash from Financing Activities (2023 - 2025)

Zenas BioPharma has reported Cash from Financing Activities over the past 3 years, most recently at $140.8 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $140.8 million for Q4 2025, up 7500.81% from a year ago — trailing twelve months through Dec 2025 was $215.3 million (down 47.87% YoY), and the annual figure for FY2025 was $215.3 million, down 47.87%.
  • Cash from Financing Activities for Q4 2025 was $140.8 million at Zenas BioPharma, up from $72.6 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for ZBIO hit a ceiling of $234.0 million in Q3 2024 and a floor of -$614000.0 in Q1 2024.
  • Median Cash from Financing Activities over the past 3 years was $1.9 million (2024), compared with a mean of $69.8 million.
  • Peak annual rise in Cash from Financing Activities hit 7500.81% in 2025, while the deepest fall reached 99.03% in 2025.
  • Zenas BioPharma's Cash from Financing Activities stood at $50000.0 in 2023, then soared by 3606.0% to $1.9 million in 2024, then soared by 7500.81% to $140.8 million in 2025.
  • The last three reported values for Cash from Financing Activities were $140.8 million (Q4 2025), $72.6 million (Q3 2025), and $1.7 million (Q2 2025) per Business Quant data.